TF and cancer: The downregulation of RFX1 has been shown to predict poor prognosis in patients with small hepatocellular carcinoma (Liu et al., 2018), while TFCP2/TFCP2L1/UBP1 has been found to act as a TF in cancer (Kotarba et al., 2018).